Shumway Capital

Elligo Health Research, Inc. is a healthcare organization focused on enhancing clinical research through innovative infrastructure and technology. Founded in 2016 and headquartered in Austin, Texas, the company facilitates the integration of clinical research into healthcare clinics, enabling faster development of pharmaceutical, biotechnology, and medical device products. By utilizing advanced health informatics and electronic health records, Elligo helps identify suitable patients for clinical trials and offers physicians the necessary support to conduct trials efficiently without the need for significant infrastructure investments. This approach not only accelerates patient enrollment and trial completion for sponsors but also allows patients to participate in clinical research within their own healthcare settings, minimizing logistical challenges and contributing to advancements in medical care. Additionally, Elligo empowers physicians with knowledge of emerging therapies, ultimately enhancing patient care and engagement in the research process.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Finch Therapeutics is a biotechnology company based in Somerville, Massachusetts, focused on developing microbial therapies for patients with serious medical needs. The company specializes in creating microbiome-based treatments to address conditions driven by dysbiosis or disruption of the microbiome. Finch Therapeutics offers two main product platforms: Full-Spectrum Microbiota and Rationally-Selected Microbiota, which aim to restore microbiome functionality. These therapies are designed to treat various conditions, including recurrent C. difficile infection, chronic hepatitis B, inflammatory bowel disease, and gastrointestinal symptoms in children with autism. The company employs machine learning algorithms to analyze clinical data from successful fecal transplantations, identifying effective microbial combinations for therapeutic use. Finch Therapeutics was founded in 2017 and has a strong intellectual property portfolio, including over 70 issued patents relevant to microbiome therapeutics.

Finch Therapeutics is a biotechnology company based in Somerville, Massachusetts, focused on developing microbial therapies for patients with serious medical needs. The company specializes in creating microbiome-based treatments to address conditions driven by dysbiosis or disruption of the microbiome. Finch Therapeutics offers two main product platforms: Full-Spectrum Microbiota and Rationally-Selected Microbiota, which aim to restore microbiome functionality. These therapies are designed to treat various conditions, including recurrent C. difficile infection, chronic hepatitis B, inflammatory bowel disease, and gastrointestinal symptoms in children with autism. The company employs machine learning algorithms to analyze clinical data from successful fecal transplantations, identifying effective microbial combinations for therapeutic use. Finch Therapeutics was founded in 2017 and has a strong intellectual property portfolio, including over 70 issued patents relevant to microbiome therapeutics.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Elligo Health Research, Inc. is a healthcare organization focused on enhancing clinical research through innovative infrastructure and technology. Founded in 2016 and headquartered in Austin, Texas, the company facilitates the integration of clinical research into healthcare clinics, enabling faster development of pharmaceutical, biotechnology, and medical device products. By utilizing advanced health informatics and electronic health records, Elligo helps identify suitable patients for clinical trials and offers physicians the necessary support to conduct trials efficiently without the need for significant infrastructure investments. This approach not only accelerates patient enrollment and trial completion for sponsors but also allows patients to participate in clinical research within their own healthcare settings, minimizing logistical challenges and contributing to advancements in medical care. Additionally, Elligo empowers physicians with knowledge of emerging therapies, ultimately enhancing patient care and engagement in the research process.

Elligo Health Research, Inc. is a healthcare organization focused on enhancing clinical research through innovative infrastructure and technology. Founded in 2016 and headquartered in Austin, Texas, the company facilitates the integration of clinical research into healthcare clinics, enabling faster development of pharmaceutical, biotechnology, and medical device products. By utilizing advanced health informatics and electronic health records, Elligo helps identify suitable patients for clinical trials and offers physicians the necessary support to conduct trials efficiently without the need for significant infrastructure investments. This approach not only accelerates patient enrollment and trial completion for sponsors but also allows patients to participate in clinical research within their own healthcare settings, minimizing logistical challenges and contributing to advancements in medical care. Additionally, Elligo empowers physicians with knowledge of emerging therapies, ultimately enhancing patient care and engagement in the research process.

Finch Therapeutics is a biotechnology company based in Somerville, Massachusetts, focused on developing microbial therapies for patients with serious medical needs. The company specializes in creating microbiome-based treatments to address conditions driven by dysbiosis or disruption of the microbiome. Finch Therapeutics offers two main product platforms: Full-Spectrum Microbiota and Rationally-Selected Microbiota, which aim to restore microbiome functionality. These therapies are designed to treat various conditions, including recurrent C. difficile infection, chronic hepatitis B, inflammatory bowel disease, and gastrointestinal symptoms in children with autism. The company employs machine learning algorithms to analyze clinical data from successful fecal transplantations, identifying effective microbial combinations for therapeutic use. Finch Therapeutics was founded in 2017 and has a strong intellectual property portfolio, including over 70 issued patents relevant to microbiome therapeutics.

Artsy is the largest online art marketplace, offering access to over one million artworks from both iconic and emerging artists. The platform collaborates with leading museums, galleries, auction houses, and art fairs to create a comprehensive space for buying and selling art. By connecting users to a global audience, Artsy not only facilitates the discovery and collection of art but also supports artists and promotes art appreciation worldwide. Additionally, the company manages online art publications, further enhancing its role in the art community.

Elligo Health Research, Inc. is a healthcare organization focused on enhancing clinical research through innovative infrastructure and technology. Founded in 2016 and headquartered in Austin, Texas, the company facilitates the integration of clinical research into healthcare clinics, enabling faster development of pharmaceutical, biotechnology, and medical device products. By utilizing advanced health informatics and electronic health records, Elligo helps identify suitable patients for clinical trials and offers physicians the necessary support to conduct trials efficiently without the need for significant infrastructure investments. This approach not only accelerates patient enrollment and trial completion for sponsors but also allows patients to participate in clinical research within their own healthcare settings, minimizing logistical challenges and contributing to advancements in medical care. Additionally, Elligo empowers physicians with knowledge of emerging therapies, ultimately enhancing patient care and engagement in the research process.

Trumid Financial LLC is a financial technology company based in New York that specializes in electronic trading solutions for the credit market. Founded in 2014, Trumid operates the Trumid Market Center, an electronic trading network specifically designed for corporate bonds, and offers Trumid Bond Stream, a tool that provides TRACE pricing data. The company focuses on enhancing the credit trading experience by integrating advanced technology with market expertise, facilitating direct access to liquidity and valuable market intelligence for professionals in the corporate bond sector. Additionally, Trumid Labs leverages data science to manage its network and provide bond price lookup services, enabling participants to make informed trading decisions. Trumid operates as a subsidiary of Trumid Holdings LLC.